|Articles|January 1, 1998

A Managed Care Appraisal of Atypical Agents in the Treatment of Psychoses
Volume 4
Issue 1 Suppl

Atypical Antipsychotics in the Managed Care Era

Author(s)Antony D. Loebel, MD, Shelia R. Botts, PharmD, Beth I. Feldman, PhD

Download PDF: Atypical Antipsychotics in the Managed Care Era

Articles in this issue

over 28 years ago

Article

Common Treatment Goals: Switching Antipsychotics

over 28 years ago

Article

Antipsychotics : Present and Future

over 28 years ago

Article

CME Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Introduction - The Routine Use of Atypical Antipsychotics

over 28 years ago

Article

Atypical Antipsychotics and Formulary Decisions

over 28 years ago

Article

Chronic Ambulatory Outpatients and Four-Vector Management

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Atypical Antipsychotics in the Managed Care Era

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care

Cardiology Prices Vary Widely by Insurer and State

Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection

Rethinking Cardiometabolic Risk: Deepak Bhatt, MD, MPH, MBA